Lovastatin Tablet
Product Images NDC 66267-506

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 66267-506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

66267 506 90

Packaging label for Lovastatin 10 mg oral tablets, containing 90 tablets per bottle. The label indicates the product is manufactured by NuCare Pharmaceuticals, Inc. in Carlsbad, CA. Tablets are round, white/off-white, and engraved with 'CT1 141' on one side. The label includes NDC 66267-506 and product number P0506090, and displays storage instructions to keep at controlled temperature 68-77°F. Warning to keep out of reach of children and that it is prescription-only (Rx Only) is noted.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin, showing its molecular configuration with multiple rings, hydroxyl group, and ester functional group typical of this active ingredient.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' listing various coadministered drugs or grapefruit juice, dosing regimens, number of subjects, lovastatin dosing, and AUC ratios comparing lovastatin exposure with and without coadministered drugs. Drugs include gemfibrozil, itraconazole, grapefruit juice (high and low dose), cyclosporine, and diltiazem.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without an event over six years of follow-up. The graph compares two groups labeled Lovastatin and Placebo, with the Lovastatin group showing a higher event-free proportion. A 37% risk reduction with Lovastatin (p < 0.001) is noted.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII' listing drug interactions associated with increased risk of myopathy/rhabdomyolysis for lovastatin. It details interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice, alongside prescribing recommendations like contraindications, dosage limits, and avoidance advice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.